Skip to main content

Table 2 Incidence of cardiac or vascular-related adverse events

From: Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

Adverse event of interest Patients reporting grade ≥3 adverse event,n Patients reporting grade≥3 adverse event with history of the adverse event,n
Hypertension 5 4
Congestive heart failure 5 3
Pulmonary hypertension 2 2
Lung disease 1 0
Renal failure 6 6